Merck & Co., Inc. vs First Trust Cloud Computing ETF — how do they compare? Merck & Co., Inc. trades at $126.26 (market cap $307.25B), while First Trust Cloud Computing ETF trades at $135.77. The key difference: Merck & Co., Inc. pays a 2.73% dividend while First Trust Cloud Computing ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, First Trust Cloud Computing ETF nearer its low. Which is the better fit depends on your goals.
| MRK | SKYY | |
|---|---|---|
Market Cap | $307.25B | — |
Sector | Health | — |
52-Week High | $129.52 | $155.17 |
52-Week Low | $77.60 | $104.16 |
Enterprise Value | $350.66B | — |
Dividend Yield | 2.73% | — |
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
SKYY trades at $136.02, down 0.06% on the day, with a bullish technical signal driven by moving averages. The ETF offers diversified exposure to the cloud computing sector, though key valuation and profitability metrics are not disclosed in the provided data. Recent news highlights ongoing investor interest in technology ETFs and the growth potential of AI-driven cloud platforms.
The outlook for SKYY is supported by strong inflows into technology ETFs and enterprise AI spending, but risks include sector volatility and competitive pressures. Analyst coverage remains positive on cloud computing's long-term growth, though specific price targets and institutional holdings data are needed for a fuller assessment.
Trailing returns across standard periods
Latest headlines on both assets
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →